"ViewRay Inc. Nasdaq VRAY maker of the worlds first and only clinical MRIguided radiation therapy system announced today outcomes data presented during the recent  Annual Meeting of the American Society for Radiation Oncology ASTRO. This data highlighted compelling early results using the companys MRIdian system for the treatment of inoperable locally advanced pancreatic cancer. Unlike any other system on the market today MRIdian allows clinicians to see the tumor and nearby softtissue anatomy throughout radiation treatments using realtime diagnostic MRvisualization. As a result MRIdians ontable adaptive radiation therapy allows doctors to respond to subtle anatomical changes observed on a daytoday basis and reshape the dose to better match the current contours of the tumor. By more accurately targeting the tumor and reducing treatment radiation dose to surrounding organs such as the duodenum small bowel stomach and liver a higher and potentially more effective radiation dose may be delivered without increasing the risks of side effects and complications for the patient. As featured in the ASTRO Scientific Session poster titled High Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer key data points and findings from the presentation include the following  The study detailed a retrospective review of  locallyadvanced pancreatic cancer patients treated with MRIdian at four institutions University of California Los Angeles University of Wisconsin VU University Medical Center Washington University.   The authors examined survival and toxicity rates for two unique cohorts of patients. One sample received a higher biologically effective dose maxBED  primarily enabled by MRIdian MRguided ontable adaptive radiotherapy. The other sample received a lower more conventional biologically effective dose maxBED  using nonadaptive therapy.   The cohort receiving a higher dose demonstrated a near doubling of median overall survival KaplanMeier estimated median overall survival of . months compared to . months.   Patients treated with higher radiation doses reported no grade  or higher toxicities  percent. In comparison those patients receiving lower doses via nonadaptive treatments experienced . percent grade  or higher toxicities. Highdefinition MR now enables oncologists to detect the slightest anatomical changes that occur from one day to the next and in realtime while the patient is being treated. Coupled with new adaptive radiation therapy software tools we create new customized plans in minutes all while the patient is on the treatment table said Percy Lee M.D. senior author and Associate Professor and Vice Chair of Education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA. The data presented at the  ASTRO Annual Meeting suggests that higher radiation doses with adaptive MR guided radiation therapy may improve survival in pancreatic cancer while maintaining a very favorable toxicity profile. These outcomes warrant further investigations. The early results highlighted above along with other data obtained using MRIdian will be tested in a multicenter prospective singlearm clinical trial for inoperable locally advanced or borderline resectable pancreatic cancer. The trial will be conducted by ViewRays Clinical Cooperative Think Tank CT a group of MRIdian medical institutions focused on evidence gathering to support MRguided radiation therapy.   For more information regarding this clinical trial please visit httpgo.viewray.compancreatic_cancer_trial_info. Presentations discussing the multiinstitutional poster in ViewRays ASTRO booth are available on the companys website at http_.  About ViewRay ViewRay Inc. Nasdaq VRAY designs manufactures and markets the MRIdian radiation therapy system. MRIdian is built upon a proprietary highdefinition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology MRIdians highdefinition MR was purposely built to deliver highprecision radiation without unnecessary beam distortion and consequently help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay Inc.  This press release contains forwardlooking statements. Statements in this press release that are not purely historical are forwardlooking statements. Such statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements with respect to predicted improved survival described in the poster presentation and video are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MRguided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer. Further studies including the planned prospective multiinstitutional study referenced in this press release as well as patient data covering longer periods of time posttreatment could lead to different or contrary results from those expressed during ASTRO or in the poster presentation. Given these uncertainties the reader is advised not to place any undue reliance on any forwardlooking statements. Additional risk factors include among others the ability to raise the additional funding needed to continue to pursue ViewRays business and product development plans the inherent uncertainties associated with developing new products or technologies competition in the industry in which ViewRay operates and overall market conditions. These forwardlooking statements are made as of the date of this press release and ViewRay assumes no obligation to update the forwardlooking statements or to update the reasons why actual results could differ from those projected in the forwardlooking statements except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at http"